Review
Gene Therapy advance online publication 17 April 2008; doi: 10.1038/gt.2008.72
Gene therapy progress and prospects cancer: oncolytic viruses
- 1Department of Clinical Research, Jennerex Biotherapeutics Inc., San Francisco, CA, USA
- 2Department of Pharmacology, School of Medicine, University of Oxford, Oxford, UK
Correspondence: Dr D Kirn, Jennerex Biotherapeutics Inc., One Market Street, Spear Tower, Suite 2260, San Francisco, CA 94105, USA. E-mail: dkirn@jennerex.com
Received 14 January 2008; Revised 7 March 2008; Accepted 10 March 2008; Published online 17 April 2008.
Abstract
The past 2 years have seen several major advances in oncolytic virotherapy. Studies on the interaction between viruses, immune responses and tumor microenvironment have provided important insight, while clinical trials have shown promise. This review summarizes key findings in this field over the past 2 years, and provides directions for future success.
Keywords:
cancer, oncolytic, virus, replication
Abbreviations:
CAR, coxsackievirus-adenovirus receptor; CIK, cytokine-induced killer; CTL, cytotoxic T lymphocyte; EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; HSV, herpes simplex virus; IFN, interferon; MMP, matrix metalloproteinase; MOA, mechanism-of-action; PBMC, peripheral blood mononuclear cells; TK, thymidine kinase; Treg, regulatory T cells; TSA, trichostatin A; VSV, vesicular stomatitis virus